Lorcaserin for Obesity

Recruiting in Palo Alto (17 mi)

Overseen byChristos S Mantzoros, MD DSc

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: Beth Israel Deaconess Medical Center

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The purpose of this protocol is to investigate, using functional magnetic resonance imaging (fMRI), the effect of treatment with lorcaserin on centers of the brain that control appetite and food intake, as well as lorcaserin's downstream metabolic effects.

Research Team

Christos S Mantzoros, MD DSc

Principal Investigator

Beth Israel Deaconess Medical Center

Eligibility Criteria

This trial is for adults with obesity (BMI > 30 or >27 with related health issues) who are not pregnant, breastfeeding, or planning pregnancy. Participants must use recommended contraception and cannot have diabetes, severe liver/renal impairment, metal implants, claustrophobia, a history of weight loss surgery, or be taking certain medications.

Inclusion Criteria

I am obese with a BMI over 30, or over 27 with related health issues.

I am using two forms of birth control as required.

Exclusion Criteria

Hypersensitivity to the active substance or any of the excipients in lorcaserin

Women using IUD (intrauterine device)

Body weight above the limitation of the MRI scanning table (330lbs/150 Kg) or body dimensions that could difficult the performance of the scan

See 26 more

Treatment Details

Interventions

Lorcaserin HCl (Serotonin Receptor Agonist)
Placebo (Other)

Trial OverviewThe study tests the effects of Lorcaserin HCl on brain centers controlling appetite using fMRI scans. It compares these effects to a placebo group to understand how the drug influences hunger and metabolism in obese individuals.

Participant Groups

2Treatment groups

Active Control

Placebo Group

Group I: ActiveActive Control1 Intervention

Subjects will be randomized to either placebo or Lorcaserin HCl.

Group II: PlaceboPlacebo Group1 Intervention

Subjects will be randomized to either placebo or Lorcaserin HCl.